Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Georg Kreuzbauer"'
Autor:
Nicolas Boissel, Sabina Chiaretti, Cristina Papayannidis, Josep-Maria Ribera, Renato Bassan, Andrey N. Sokolov, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Gerhard Zugmaier, Robin Foà, Alessandro Rambaldi
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract This retrospective observational study (NEUF) included adult patients with B-cell acute lymphoblastic leukemia (B-cell ALL) who had received blinatumomab for the treatment of minimal residual disease-positive (MRD+) or relapsed/refractory (R
Externí odkaz:
https://doaj.org/article/85db980c2878469ba6f0b8379f5e0d97
Autor:
Paolo Ghia, Manan Pareek, Shogheeg Apkarian Bourjlian, Naghmana Bajwa, Anthony J. Corry, Suman Jannuru, Georg Kreuzbauer, Husam Abdel-Qadir
Publikováno v:
HemaSphere, Vol 7, p e055170d (2023)
Externí odkaz:
https://doaj.org/article/85bccda82c3f419595bf5cc11b221aa9
Autor:
Renato Bassan, Monika Brüggemann, Hoi-Shen Radcliffe, Elizabeth Hartfield, Georg Kreuzbauer, Sally Wetten
Publikováno v:
Haematologica, Vol 104, Iss 10 (2019)
Minimal (or ‘measurable’) residual disease in acute lymphoblastic leukemia appears to be a prognostic indicator, with potential value in informing individualized treatment decisions. Complete understanding of the strength of the association betwe
Externí odkaz:
https://doaj.org/article/e805af1b82014214b36cdbc7b4dc200c
Autor:
Franco Locatelli, Alexey Maschan, Nicolas Boissel, Luisa Strocchio, Naufil Alam, Isabella Pezzani, Alessandra Brescianini, Georg Kreuzbauer, Andre Baruchel
Publikováno v:
Pediatric Blood & Cancer. 69
Prior to regulatory approval of blinatumomab in pediatric patients with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (R/R Ph- BCP-ALL), blinatumomab was made available via an expanded access progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9748524a2115a6a02e2b24970dd96c2
https://doi.org/10.1002/pbc.29562
https://doi.org/10.1002/pbc.29562
Autor:
Louise Taylor, Anouchka Seesaghur, Martin R. Schipperus, Georgia Kaiafa, Georg Kreuzbauer, Sally Wetten, Andy Boshier
Publikováno v:
Drug Safety
Introduction Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved in the European Union for self-administration (or administration by a caregiver) in selected adult patients with chronic primary immune thrombocytopeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c613ea46a4c680442216f3f1de0293d
https://doi.org/10.1007/s40264-018-0723-6
https://doi.org/10.1007/s40264-018-0723-6
Autor:
Georg Kreuzbauer, Naufil Alam, Alessandro Rambaldi, Xavier Thomas, Alexandros Spyridonidis, Nicola Stefano Fracchiolla, Anita W. Rijneveld, Cyril Šálek, William Kormany, Abeera Mohammad, Sabina Chiaretti, Isabella Pezzani Grueter
Publikováno v:
Blood. 136:38-39
Background: Blinatumomab is approved for the treatment of adult patients (pts) with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukaemia (R/R Ph- BCP-ALL). We present interim 3-year results of a multi-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6ace0c634867721212bee4b9e74064a
https://doi.org/10.1182/blood-2020-134470
https://doi.org/10.1182/blood-2020-134470
Autor:
Marieke Schoonen, Georg Kreuzbauer, Hans Wadenvik, Michael Steurer, Philippe Quittet, Dominik Selleslag, Jean-François Viallard, Tomas Kozak, Ann Janssens, Helen A. Papadaki, Georgia Kaiafa, Laura Belton
Publikováno v:
European Journal of Haematology. 98:112-120
Objective Romiplostim has maintained long-term platelet counts in patients with immune thrombocytopenia (ITP) for up to 5 years in clinical studies. This prospective observational study aimed to describe romiplostim utilisation and outcomes in Europe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df3d4c72a64b0214676b682176f49e1c
https://doi.org/10.1111/ejh.12807
https://doi.org/10.1111/ejh.12807
Autor:
Leyla Agaoglu, Vít Procházka, Waldemar Tomczak, Malgorzata Zajac, Kosuke Obama, Peter Turcsanyi, Melek Ergin, Paul Woodard, Michael Steurer, Marcia Torresan Delamain, Maria Luiza Macedo Silva, Irene Lorand-Metze, Krzysztof Warzocha, Wieslaw Wiktor-Jedrzejczak, Sylwia Chocholska, Georg Kreuzbauer, Semra Paydas, Carmino Antonio De Souza, Dulcinéia Martins Albuquerque, Emanuele Angelucci, Ann Janssens, Vehbi Ercolak, Krzysztof Giannopoulos, Maria Helena Morgani de Almeida, Beatriz Felicio Ribeiro, Druckerei Stückle, Ralph V. Boccia, Emine Bagir, Gulsah Seydaoglu, Michael Tarantino, Koichi Miyamura, Bruna Rocha Vergílio, Rony Schaffel, Thomas Liehr, Robert J. Bird, Meral Gunaldi, Tomas Papajik, Agnieszka Karczmarczyk, Maciej Grzywnowicz, Vagner Oliveira Duarte, Rosana Antunes da Silveira, Cigdem Usul Afsar, Andrey Dos Santos, Katarzyna Skorka, Yurdanur Kilinç, Renata Binato, Katia B Pagnano, Mariana Tavares de Souza, Joanna Zaleska, Roberto R. Capela de Matos, Sabine Glaser, Martin Novak, Basak Yavuz, Amanda Faria de Figueiredo, Eyad Alhourani, Berna B. Duman, Urabe A, Eliana Cristina Martins Miranda, Kahraman Tanriverdi, Maria Fernanda López Fernández, Lay Cheng Lim, Gislaine Borba Oliveira-Duarte, Maria Gabriella Mazzucconi, Candace Wang, Satz Mengensatzproduktion, Peter te Boekhorst, Raul C. Ribeiro, Hikmet Celik, Yutaka Kohgo, Kerry Dillingham, Tomas Kozak
Publikováno v:
Acta Haematologica. 134:I-IV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34ae4e0ef8036c0f683e78d639fd632a
https://doi.org/10.1159/000441854
https://doi.org/10.1159/000441854
Autor:
Naufil Alam, Georg Kreuzbauer, Renato Bassan, Alessandro Rambaldi, Cristina Papayannidis, Josep-Maria Ribera, Alessandra Brescianini, Isabella Pezzani, Nicolas Boissel, Robin Foà, Sabina Chiaretti
Publikováno v:
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background: Blinatumomab is approved in Europe for adult and pediatric patients (pts) with relapsed and/or refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (R/R Ph- BCP-ALL), and for adult pts with minimal res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::860f0455b0248120fdd25ad1f5fa8eb2
https://doi.org/10.1182/blood-2019-122917
https://doi.org/10.1182/blood-2019-122917
Autor:
Naufil Alam, Georg Kreuzbauer, Renato Bassan, Nicolas Boissel, Sabina Chiaretti, Josep-Maria Ribera, Isabella Pezzani, Cristina Papayannidis, Alessandra Brescianini, Robin Foà, Alessandro Rambaldi
Publikováno v:
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Introduction: In November 2015, conditional approval of blinatumomab was granted for adults with relapsed and/or refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (R/R Ph- BCP-ALL). Prior to country-specific re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::231483d1db7d64d8660c08db909afca8
https://doi.org/10.1182/blood-2019-122931
https://doi.org/10.1182/blood-2019-122931